

Evaluation of genotyping methods and the relative cost of pharmacogenomics

A. DE MONACO, M. BERRETTA¹, S. PUGLIESE², D. VALENTE³,
S. CIAFFARAF³, R. DI FRANCA

Laboratory of Molecular Haematology, National Cancer Institute, Fondazione "G. Pascale" IRCCS, Naples, Italy

¹Department of Medical Oncology, CRO National Cancer Institute, IRCCS Aviano (PN), Italy

²CETAC Research Center, Caserta, Italy

³Italian Association of Pharmacogenomics and Molecular Diagnostics, Naples, Italy

Abstract. – Recently, several methods to assess the quality of cost-effectiveness, cost-utility and cost-benefit in the pharmacogenomic field have become available. A relevant example is the National Institute for Health and Clinical Excellence (NICE). NICE forms a diverse clinical Advisory committee, which stimulates Pharma and Academic communities to produce a robust set of data, including the design and data source, for economic models of personalized healthcare. Personalized medicine includes genomic tests of each patients and their disease into their clinical treatments, so as minimize toxicity and maximize benefits. It is well known that Pharmacogenomics (PG) tests, performed before drug treatment, lower overall medical costs and provide higher quality of life and longer life expectancy. In this issue relative costs of genotyping methods and platforms, were evaluated by "manually cured criteria" due to lack of specific guidelines. Finally, with the progress made in this scenario over the next five years, health decision-making may be able to accelerating the translation of genetic technologies into routine clinical laboratory.

Key Words:

Pharmacogenomics, Genotyping methods, Molecular diagnostics, Pharmacoeconomy, Clinical laboratory.

Introduction

Promise in the future, a disease could be ranked into genetic categories, allowing bespoke tailoring of medicine to maximize therapeutic effects and to reduce the potential for adverse drug response.

As genomics-based technologies are widely introduced in clinical laboratories testing setting, the risks of mishandling or misinterpreting data from patient's sample analyses becomes a significant consideration with especially dramatic consequences where the test becomes commercially available to the public¹.

Generally, genotyping is performed either by custom service laboratories or academic referenced laboratories, as well as by using commercial kits (when available). In the USA, diagnostics products are regulated by the *Food and Drug Administration* (FDA), whereas diagnostic services are under the rules of the *Clinical Laboratory Improvement Act* (CLIA). In Europe this field is covered by *in vitro Diagnostic* (IVD) directive, without a distinction between commercial products (used by laboratories) and diagnostics service. In both case, a voluntary list of international laboratories (with CLIA certification in the US) able to perform genetic tests can be found on the National Institute of Health-funded website named GeneTests™ www.ncbi.nlm.nih.gov/sites/GeneTests/lab?db=GeneTests, although only a small minority of genetic tests listed on this site are Pharmacogenomics (PG) tests. Clinical laboratories may develop and validate tests in-house ("home-brew") and perform them as a laboratory service; which may further reduce the cost of analysis².

Pharmaceutical and Biotech companies frequently develop their own clinical pharmacokinetic and pharmacodynamic tests for new drug

Abbreviations

PG = Pharmacogenetics and pharmacogenomics; NICE = National Institute for Health and Clinical Excellence; SNPs = Single Nucleotide Polymorphisms; SSCP = Single-Strand Conformational Polymorphism; FRET = Fluorescent Resonance Energy Transfer; MALDI TOF Matrix-Assisted Laser Desorption/Ionization Time Of Flight; ASA-PCR = Allele Specific Amplification-Polymerase Chain Reaction; RFLP = Restriction Fragment Length Polymorphism; D-HPLC = Denaturing-High Performance Liquid Chromatography; FDA = Food and Drug Administration; CE = European Community; UGT1A1 = Uridine diphosphate Glucuronosyl Transferase 1A1.

studies. They are required to have validated assays for human clinical phase III trials complying with current Good Clinical Practice guidelines for FDA or EMEA submission purposes. This involves testing patients as a potential recipients before the administration of the drug. This difference poses an ethical dilemma for pharmaceutical companies, especially if inadequate testing excludes some patients who might benefit from receiving the drug or, conversely, long-term dosing continues with a treatment that does not have good clinical efficacy. Pharmaceutical companies should be involved with the initial development of PG assays because they have the primary data and information necessary for this stage of assay development. However, this assay development activity should be transferred to outside referenced laboratories, clinical core laboratories in academic health centers, or established Clinical Research Organizations when research and development transit into clinical application because these independent external sites are able to handle this function³.

Reimbursement or payment for genetic testing is another topic of considerable consequence that is already creating controversy among health maintenance organizations, healthcare providers, and the patients themselves. One can predict, however, that health insurance companies will be very interested in patient PG testing to document the proper dosing of expensive prescription drugs and hence reduce the incidence or risks of adverse drug reactions. It will be interesting to see whether insurers will consider PG testing to be a cost-effective alternative to the current trial-and-error approach to dosage regulation. However, if the detection of these genetic variants is routinely incorporated either into clinical practice or large clinical trials, knowledge concerning the predictive value of PG which will eventually enable the individualization of optimized therapy could be gained⁴.

Several methods to assess the quality of cost-effectiveness, cost-utility and cost-benefit of PG tests have become available. A relevant example is the National Institute for Health and Clinical Excellence (NICE). NICE forms a Diagnostic Advisory committee, which stimulates Pharma and Academic communities to produce a robust set of data, including the design and data source, for economic models of healthcare⁵.

Relative costs of PG tests, here, were evaluated by “manually cured criteria” due to lack of specific guidelines.

We wish to stress that the cost-effectiveness, cost-utility and cost-benefit analysis (i.e. toxicity-related hospitalization) are not considered here.

The goal of this issue is to provide information on the advantages and limitations, in terms of costs, of the most common available methods for molecular detection of polymorphisms related to drug therapy.

We believe that retrospective and prospective trials evaluating the pharmacoeconomic impact of genotyping testing will provide answers on the possibility to incorporate PG testing into routine clinical practice.

Current Genotyping Methods for Known Mutations

The most popular platforms for the detection of known SNPs can be classified in two major groups (1) platforms discriminating alternative alleles (mutant *vs* wild type) and (2) platforms detecting mutant alleles in a given DNA. The only platform able to detect and discriminate the alleles is MALDI TOF. There are also other allele discrimination methods, although not as powerful MALDI-TOF, including: (1) PCR-based without fluorescent probe (ASA, SSCP and RFLP); (2) methods combining PCR with hybridization probes (FRET-based platforms, Invader assay and LNA Probes); (3) PCR-based with intercalating fluorescent dye as High Resolution Melting (HRM); (4) PCR required only for sample pre-treatment as Denaturing-High Performance Liquid Chromatography (D-HPLC).

The principal methods used to detect mutant alleles in given DNA, are: (1) Pyrosequencing (require a PCR pre-treatment); (2) PNA mediated clamping-PCR; (3) Gene chip technologies; and (4) sequencing methods.

New high-throughput sequencing technologies are incorporated in new platforms such as: 1G Genetic analyzer by Illumina/Solexa (Cambridge, UK), SOLiD by Life technologies (Foster City, CA, USA) and Genome Sequencer FLX by Roche Diagnostics (Brandfort CT USA). These “Next Generation DNA Sequencers” provide a consensus base accuracy of 99.99%.

Non-PCR-based technologies, such as the Golden Gate[®] Assay and DNA chip-based microarray are the latest development in the genotyping arena. These technologies are able to directly genotype genomic DNA without PCR amplification. These new technologies are not widely used in the general clinical laboratory setting compared to PCR-based methods.

The qualitative assessments of the SNPs are performed without a necessary gold standard method for the daily diagnostic routine (Table I).

Genotyping Costs

Furthermore, trials evaluating the pharmaco-economic impact of genotyping testing before therapy will likely provide answers for policy making in the merging of PGx testing into clinical practice. The primary aim of a cost-effectiveness analysis is to provide sufficiently robust information for decision-makers to allocate resources to healthcare interventions. Overviews of cost-effectiveness studies on PGx technologies are now available⁵. A relevant example is the NICE: a Diagnostic Advisory committee, which is willing to stimulate Pharma and Academic communities to produce a robust set of data, including design and data source in economic models of healthcare⁶.

Only few studies have addressed the cost-effectiveness of pharmacogenomics testing implication in clinical practice. For example, Aquilante et al⁷ performed a study to compare the accuracy, the rapidity, and the cost of two methodologies used for genotyping a single variant in the cytochrome P450 (*CYP*) 2C9 metabolizing enzyme gene: the cost/sample for 1 SNP detection was (US dollars) \$1.90 by PCR-Pyrosequencing and \$3.14 by RFLP. Other Authors,

included thiopurine S-methyltransferase (TPMT) genotyping prior to 6-mercaptopurine treatment in paediatric Acute Lymphoblastic Leukaemia (ALL); the mean calculated cost from 4 European countries was €2100,00 per life-year considering low myelosuppression-related hospitalization; the cost for genotyping of TPMT mutation averaged around €150,00⁸. In addition, Gold et al⁹ concluded that pharmacogenetic testing for UGT1A1*28 variant homozygosity before Irinotecan treatment may be cost effective. The genotype testing cost is averaged \$103.00.

Early outline of genotyping cost for “home brew” pharmacogenomic tests is averaged about €20,00 per SNP¹⁰.

Conclusions and Future Outlook

It is well known that PG tests, performed before drug treatment, allowing the overall medical costs and provide higher quality of life and personalized treatments. However, we still need a precise evidences that PG tests offer an added value, in terms of relative cost and benefit¹¹.

The usefulness of the variants in clinical practice depends on improving the diagnostic prediction or fostering changes in prevention or treatment strategies¹². We are now entering the era of Molecular Diagnostics, which is bringing forth the newest and most powerful science and tech-

Table I. Most common platforms used for genotyping at molecular level.

Genotyping methods to detect known SNP	Instrument mean costs [§]	Approximate reagent costs per SNP [§]	Approximate time-labour per SNP [#]
Conventional sequencing*	++	Low	Moderate
SSCP	+	Low	Very laborious
Allele Specific Amplification (ASA)	+	Very low	Moderate
Restriction Fragment Length Polymorphism (RFLP)	+	Very low	Very laborious
FRET probe allelic discrimination)	++	Moderate	Moderate
(Hyb Probe® TaqMan®, Beacons® Scorpions®)			
Locked Nucleic Acid (LNA) probe	++	Moderate	Moderate
Oligo ligation assay (SNPlex®)	+++	High	Fast
PCR-Invader® Assay	+++	High	Fast
High resolution melting (HRM)	++	Low	Moderate
Pyrosequencing*	+++	High	Fast
Peptide nucleic acid-mediated Clamping PCR*	+	Moderate	Moderate
Gene Chip technology (LabOnChip)*.	+++ /++++	Very high	Moderate
Maldi-TOF	++++	Very high	Moderate
Next Generation sequencing	++++	Very high	Very fast
D-HPLC	++++	Moderate	Very fast

[§]Approximate instrumentation list price were scored as + (< 10000€); ++ (< 50000€); +++ (< 100000€), ++++ (> 100000€);

[§]Reagent costs were scored as very low (< 5€), low (< 10€), moderate (< 30€), high (< 50€), very high (> 50€). [#]Time-labour refers input needed to perform a single test of multiple samples. It were scored as very fast (< 1 hour), fast (< 4 hours), moderate (< 1 day), laborious (< 2 day) very laborious (> 2 working day). *No address to allelic discrimination (mutant vs wild type).

nology available for the modern-day practice of diagnostic laboratory medicine¹³. There is a compelling need for more detailed and extensive studies to establish the cost and effectiveness of genotyping. Although there are still unanswered questions, PG researchers have generated and improved specific tools for novel treatment and handling of cancer patients. With new PG markers being identified and validated, physicians will have ways and means to tailor specific drugs to individual genetic profiles¹⁴. Furthermore, the clinical interpretation of PG testing became integrated in the physician's expertise¹⁵.

Over the next few years, the emergence of molecular resistance to new therapies as a result of genomic alterations in cancer will drive diagnostics companies to develop new tests for individualized therapy. The future implementation of the methods for genotyping will lead to personalized treatment and eventually will shift the balance from disease relapse toward disease eradication¹⁶. Therefore, it is essential that pharmaceutical and biotechnology companies join the efforts to develop accurate and cheap tests for routine diagnostics in pharmacogenomics.

Conflict of Interest

The Authors declare that there are no conflicts of interest.

References

- 1) DEVERKA PA. Pharmacogenomics, evidence, and the role of payers. *Public Health Genomics* 2009; 12: 149-157.
- 2) DI FRANCIA R, FRIGERI F, BERRETTA M, CECCHIN E, ORLANDO C, PINTO A, PINZANI P. Decision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics. *Clin Chem Lab Med* 2010; 48: 447-445.
- 3) CROWFORD JM AND ASPINALL MG. The business value and cost-effectiveness of genome medicine. *Personalized Medicine* 2012; 9: 265-286.
- 4) BALBOA E, DURAN G, LAMAS MJ, GOMEZ-CAAMAÑO A, CELEIRO-MUÑOZ C, LOPEZ R, CARRACEDO A, BARROS F. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. *Pharmacogenomics* 2010; 11: 747-761.
- 5) DHALLA IA, GARNER S, CHALKIDOU K, LITTLEJOHNS P. Perspectives on the National Institute for Health and Clinical Excellence's recommendations to use health technologies only in research. *Int J Technol Assess Health Care* 2009; 25: 272-280.
- 6) PAYNE K, SHABARUDDIN FH. Cost-effectiveness analysis in pharmacogenomics. *Pharmacogenomics* 2010; 11: 643-646.
- 7) AQUILANTE CL, LOBMEYER MT, LANGAEE TY, JOHNSON JA. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. *Pharmacotherapy* 2004; 24: 720-726.
- 8) VAN DEN AKKER-VAN MARLE ME, GURWITZ D, DETMAR SB, ENZING CM, HOPKINS MM, GUTIERREZ DE MESA E, IBARRETA D. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. *Pharmacogenomics* 2006; 7: 783-792.
- 9) GOLD HT, HALL MJ, BLINDER V, SCHACKMAN BR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. *Cancer* 2009; 115: 3858-3867.
- 10) DI FRANCIA R, BERRETTA M, CATAPANO O, CANZONIERO LM, FORMISANO L. Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications. *Clin Chem Lab Med* 2011; 49: 1105-1111.
- 11) DE MONACO A, VALENTE D, DI PAOLO M, TROISI A, D'ORTA A, DEL BUONO A. Oxaliplatin-based therapy: strategies to prevent or minimize neurotoxicity. *W Cancer Res J* 2014; 1: e232.
- 12) DI FRANCIA R, CIMINO L, BERRETTA M. Genetic variants influencing fluoropyrimidine based-therapy and available methods to detect them. *Eur Rev Med Pharmacol Sci* 2012; 16: 285-298.
- 13) DI FRANCIA R, CATAPANO O, PEZONE A, LUS G, BERRETTA M, DEL PUP L, DE LUCIA D. Molecular diagnostics in the clinical practice – "Research Centre CETAC" Caserta (Italy) the 23/24 May 2014. *W Cancer Res J* 2014; 1: e220.
- 14) BERRETTA M, DI FRANCIA R, TIRELLI U. The new oncologic challenges in the 3rd Millenium. *W Cancer Res J* 2014; 1: e133.
- 15) DI FRANCIA R, VALENTE D, PUGLIESE S, DEL BUONO A, BERRETTA M. What health in oncology needs to know about pharmacogenomics? *W Cancer Res J* 2014; 1: e90.
- 16) DALZOVO L. About a "Cancer Survivor". *W Cancer Res J* 2014; 1: e252.